Crenolanib (CP-868596)

Catalog No. A11052

Crenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations.
  • N Naganna, .et al. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice, EBioMedicine, 2019, Jan 24. pii: S2352-3964(19)30012-X PMID: 30686755
Catalog Num A11052
M. Wt 443.5
Formula C26H29N5O2
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 670220-88-9
Synonyms CP868596, CP 868596
SMILES CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
Crenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations.
Targets
PDGFRα (CHO cells) PDGFRβ (CHO cells)
2.1 nM(Kd)3.2 nM(Kd)
In vitro (25°C) DMSO 89 mg/mL heating (200.65 mM)
Water <1 mg/mL (<1 mM)
Ethanol 7 mg/mL (15.78 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 22.55 mL 112.74 mL 225.48 mL
0.5 mM 4.51 mL 22.55 mL 45.1 mL
1 mM 2.25 mL 11.27 mL 22.55 mL
5 mM 0.45 mL 2.25 mL 4.51 mL

*The above data is based on the productmolecular weight 443.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.